Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ross Camidge

Showing results (31-40 of 317) with videos related to

Pageof 32
Sort By:
The Lancet. Respiratory Medicine|March 30, 2019
Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutationsJose M Pacheco, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2021
Molecular Profiling of the Cerebrospinal Fluid in Leptomeningeal NSCLC: The Shape of Things to Come?David Chun Cheong Tsui, D Ross Camidge
Clinical Lung Cancer|December 5, 2022
Pregnancy and Pathways to Motherhood in Oncogene-driven Lung Cancer: A Single Institution ExperienceEmily A Simons, Tejas Patil, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 2, 2008
The insulin-like growth factor pathway in lung cancerRafal Dziadziuszko, D Ross Camidge, Fred R Hirsch
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2009
ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancerBenjamin Solomon, Marileila Varella-Garcia, D Ross Camidge
Clinical Lung Cancer|July 28, 2009
The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancersD Ross Camidge, Rafal Dziadziuszko, Fred R Hirsch
JTO Clinical and Research Reports|August 2, 2024
L2086F Mutant ROS1-Rearranged NSCLC Resistant to Repotrectinib Responds to Cabozantinib: A Case ReportUrs Weber, Kurtis D Davies, D Ross Camidge
Annals of Translational Medicine|October 3, 2019
Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remainJose M Pacheco, Dexiang Gao, D Ross Camidge
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2006
Dynamic and modern: bringing the ethics of phase I trials up to dateD Ross Camidge, S Gail Eckhardt, Lia Gore
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 15, 2022
Extending Our Reach: Expanding Enrollment in Brain Metastases and Primary Brain Tumor Clinical TrialsEudocia Q Lee, D Ross Camidge, Gautam Mehta
Pageof 32

Showing results (31-40 of 317) with videos related to

Sort By:
Pageof 32
The Lancet. Respiratory Medicine|March 30, 2019
Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutationsJose M Pacheco, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2021
Molecular Profiling of the Cerebrospinal Fluid in Leptomeningeal NSCLC: The Shape of Things to Come?David Chun Cheong Tsui, D Ross Camidge
Clinical Lung Cancer|December 5, 2022
Pregnancy and Pathways to Motherhood in Oncogene-driven Lung Cancer: A Single Institution ExperienceEmily A Simons, Tejas Patil, D Ross Camidge
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 2, 2008
The insulin-like growth factor pathway in lung cancerRafal Dziadziuszko, D Ross Camidge, Fred R Hirsch
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2009
ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancerBenjamin Solomon, Marileila Varella-Garcia, D Ross Camidge
Clinical Lung Cancer|July 28, 2009
The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancersD Ross Camidge, Rafal Dziadziuszko, Fred R Hirsch
JTO Clinical and Research Reports|August 2, 2024
L2086F Mutant ROS1-Rearranged NSCLC Resistant to Repotrectinib Responds to Cabozantinib: A Case ReportUrs Weber, Kurtis D Davies, D Ross Camidge
Annals of Translational Medicine|October 3, 2019
Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remainJose M Pacheco, Dexiang Gao, D Ross Camidge
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2006
Dynamic and modern: bringing the ethics of phase I trials up to dateD Ross Camidge, S Gail Eckhardt, Lia Gore
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 15, 2022
Extending Our Reach: Expanding Enrollment in Brain Metastases and Primary Brain Tumor Clinical TrialsEudocia Q Lee, D Ross Camidge, Gautam Mehta
Pageof 32